FDG PET-CT in Fever of Unknown Origin Analysis
Uncover the benefits of using FDG PET-CT in fever of unknown origin and its impact on diagnostic accuracy and patient care.
FDG PET-CT in Fever of Unknown Origin Analysis Read Article »
Radionuclide therapy, also known as targeted radiotherapy or molecular radiotherapy, is a type of cancer treatment that utilises radioactive substances to target and destroy cancer cells. This therapy has emerged as a powerful and versatile tool in managing various malignancies, offering a personalised approach to cancer treatment. With fewer side effects than traditional external beam radiation and chemotherapy, radionuclide therapy provides a promising option for cancer patients.
Mechanism of Action
Radionuclide therapy delivers targeted radiation to cancer cells with the help of a radiopharmaceutical agent. The radiopharmaceutical, which is a compound containing a radioactive isotope, is administered into the patient’s bloodstream, either orally or intravenously. This compound then selectively binds to specific proteins or receptors present on the surface of cancer cells.
Once bound, the radiopharmaceutical emits radiation, typically in the form of beta particles or alpha particles. These particles travel a short distance, causing localised damage to the DNA of cancer cells while minimising harm to surrounding healthy tissue. The targeted destruction of cancer cells leads to cell death and, eventually, tumour shrinkage.
Types of Radionuclide Therapy
Several types of radionuclide therapy are classified based on the radioactive isotopes used and their mechanisms of action. Some common examples include:
Benefits and Limitations
Radionuclide therapy offers several advantages over traditional cancer treatments. As a targeted therapy, it reduces damage to healthy tissue and can lead to fewer side effects. Additionally, it can be used as a standalone treatment or in conjunction with other therapies, such as chemotherapy or surgery.
However, radionuclide therapy also has its limitations. Not all cancers can be treated with this method, and sometimes, the radiopharmaceuticals do not effectively target the cancer cells. The treatment’s efficacy may also be limited by tumour size and location.
You are here:
home »
Uncover the benefits of using FDG PET-CT in fever of unknown origin and its impact on diagnostic accuracy and patient care.
FDG PET-CT in Fever of Unknown Origin Analysis Read Article »
Discover how radiopharmaceuticals in medicine are transforming diagnostics and treatments with atomic precision for better health outcomes.
Inside Radiopharmaceuticals: Tracing the Future of Medicine with Atomic Precision Read Article »
Learn how radiotheranostics in cancer care combines imaging and therapy for better outcomes in advanced malignancies.
Radiotheranostics: The Dual Power of Diagnosis and Therapy in Modern Medicine Read Article »
Learn how bioengineered contrast agents enhance imaging clarity and accuracy in nuclear medicine. Discover their unique benefits.
Bioengineered Contrast Agents: The Future of Precision in Nuclear Medicine Imaging Read Article »
Alpha particle emitting radionuclides are highly effective in delivering targeted radiation therapy for various cancers.
Selected Alpha Particle Emitting Radionuclides for Therapeutic Nuclear Medicine Read Article »
Strontium-89 Chloride Therapy delivers targeted beta emissions to osteoblastic lesions, often reducing malignant bone pain substantially.
Rhenium-188 Etidronate effectively targets metastatic bone lesions, delivering therapeutic beta radiation while reducing associated pain.
Lutetium-177 Debio 1124, a second-generation theranostic agent, selectively targets CCK2R-expressing tumours, offering precision radiotherapy and personalised oncology advancements.
Peptide Receptor Radionuclide Therapy utilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment outcomes significantly.
Iodine-131 Metuximab (Licartin) selectively targets CD147 receptors, delivering beta radiation to hepatocellular carcinoma cells, improving treatment precision significantly.
Radiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy.
The Future of Radiotheranostics: A New Frontier in Precision Medicine Read Article »
Peptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Article »
Dosimetry in radionuclide therapy plays a crucial role in optimising treatment effectiveness and ensuring patient safety and well-being.
Precision in Treatment: The Role of Dosimetry in Radionuclide Therapy Read Article »
The innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Article »
Gallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Targeting Hepatocellular Carcinoma: The Emerging Role of Girentuximab Read Article »
Utilising CXCR4 targeting agents with labelled ligands marks a breakthrough in treating haematological malignancies effectively.
CXCR4 Targeting Agents for Haematologic Malignancies Read Article »
PSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.
Overview on the central role of chelation in labelling radiocompounds.
Basic premises to molecular imaging and radionuclide therapy Read Article »
Targeted radionuclide therapy potential role in nuclear medicine drawing a parallel to iodide-131 in treatment of thyroid abnormalities.